Helsinki, Finland (May 27th, 2025) Surgify Medical, a Finnish medical technology company focused on improving the safety and precision of bone surgery with its Surgify Halo™ technology, has successfully raised €7 million in Series A funding.
With the investment, the company plans to take the next steps toward becoming a leading supplier in the multi-billion-dollar market for bone surgery devices. Building on a successful Nordic market launch, the company will expand its operations in the EU and the United States, where key hospitals have already started adopting the technology.
The funding round was led by ZEISS Ventures, the corporate venture arm of the Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Lednil and Cascara Ventures, also participated in the financing.
Conventional surgical drills spin tens of thousands of times per minute and can be dangerous if they come into contact with critical soft tissue. At worst, such soft tissue damage can result in severe injury to the patient. Soft tissue injuries are considered a highly relevant surgical complication in many types of head, neck, and spine procedures involving bone resection and result in over €4 billion in annual complication-related costs globally.
Surgify Halo™ cuts bone while providing unique protective capabilities against incidental injuries to soft tissues such as central nervous system structures, blood vessels, and nerves. The technology provides effective bone resection in combination with a soft tissue protection feature for enhanced safety and precision in surgical procedures. The Surgify Halo™ is MDR and FDA-approved and preferred by surgeons for its handling and ease of use, while integrating seamlessly into standard clinical practices.
“ZEISS brings unparalleled experience in surgical technology and a global network, while the EIC’s continued support and earlier grant financing underscore the European innovation ecosystem’s confidence in our solution,” said Visa Sippola, Co-founder and CEO of Surgify Medical. “With this funding and regulatory approvals in both the EU and the U.S., we are well-positioned to bring our unique technology to more surgeons and patients internationally.”
“Surgify’s technology is a major breakthrough in today’s evolving healthcare landscape. With over a thousand patient procedures, Surgify HaloTM has already left a significant footprint in the field. The company aims to protect patients, save costs, and has already achieved groundbreaking developments in robotic surgery applications,” stated Alan Raffensperger, Chairman of Surgify Medical.
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo™ burrs offer exceptional control at cutting rates comparable to traditional burrs, while simultaneously safeguarding delicate soft tissues. This makes the switch to Halo™ burrs an obvious choice for surgeons,” explains Dr. Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their solution on a global scale.”
“The EIC Fund is proud to support Surgify’s groundbreaking approach to safer and more precise bone surgery. Their technology holds strong potential to significantly improve surgical outcomes and patient safety globally,” says Svetoslava Georgieva, Chair of the EIC Fund Board.
###
For additional information
Visa SippolaCEO & Co-founder, Surgify Medical
visa.sippola@surgifymedical.com
+358 50 353 1232
About Surgify Medical
Surgify Medical, based in Espoo, Finland, is dedicated to revolutionizing bone surgery by making it safer, faster, and more precise. The company’s flagship product, Surgify Halo™, is designed to differentiate between hard and soft tissues, providing enhanced protection against incidental soft tissue damage and streamlining procedures.
The benefits of Surgify Halo™ extend beyond its core market of head, neck, and spine surgeries. Surgify’s technology also has the potential to revolutionize the growing field of robotic surgery by enabling reliable automated bone resection.
In 2024, the Surgify Halo™ was awarded the prestigious Red Dot Award: Innovative Product 2024, earning international recognition for its exceptional design, advanced materials, and pioneering approach to surgical innovation.
To date, Surgify Medical has raised €14M in total funding and has offices in Finland, Sweden, Denmark and the United States.
For more information, visit www.surgifymedical.com.
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
Further information at www.zeiss.com
About the European Innovation Council Fund (EIC Fund)
The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated with Horizon Europe. It provides the investment component of the EIC Accelerator blended finance. The European Investment Bank acts as an investment adviser to the EIC Fund.
The EIC Fund aims to fill a critical financing gap, and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding. The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.
Learn more at: eic.ec.europa.eu.